Mitogen-activated protein kinase signalling and ERK1/2 bistability in asthma

Clinical and Experimental Allergy

Volumn 41, Issue 2, 2011, Pages 149-159

  Alam, R ^a,b   Gorska, M M ^a,b  

^a DEPARTMENT OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASPERGILLUS; B LYMPHOCYTE; BRONCHUS; CYTOKINE RELEASE; DENDRITIC CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STABILITY; EOSINOPHIL; EPITHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; MACROPHAGE; MAST CELL; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAGWEED POLLEN; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN INFLAMMATION; T LYMPHOCYTE; ULTRAVIOLET B RADIATION;

ANIMALS; ASTHMA; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 78651442474     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03658.x     Document Type: Review

References (130)

1. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004; 68:320-44.
2. Rincón M, Davis RJ. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 2009; 228:212-24.
3. Brown MD, Sacks DB. Protein scaffolds in MAP kinase signalling. Cell Signal 2009; 21:462-9.
4. Yao Y, Li W, Wu J et al. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation. Proc Natl Acad Sci USA 2003; 100:12759-64.
5. Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R. Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 2008; 121:893-902.
6. Li B, Tournier C, Davis RJ, Flavell RA. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation. EMBO J 1999; 18:420-32.
7. Nakakuki T, Birtwistle MR, Saeki Y et al. Ligand-specific c-Fos expression emerges from the spatiotemporal control of ErbB network dynamics. Cell 2010; 141:884-96.
8. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3:859-68.
9. Tefft JD, Lee M, Smith S et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol 1999; 9:219-22.
10. Bhavsar P, Khorasani N, Hew M, Johnson M, Chung KF. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010; 35:750-6.
11. Nath P, Leung SY, Williams A et al. Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness. Eur J Pharmacol 2006; 544:160-7.
12. Atherton HC, Jones G, Danahay H. IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol 2003; 285:L730-9.
13. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-88.
14. Lee PJ, Zhang X, Shan P et al. ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo. J Clin Invest 2006; 116:163-73.
15. Tachdjian R, Mathias C, Al Khatib S et al. Pathogenicity of a disease-associated human IL-4 receptor allele in experimental asthma. J Exp Med 2009; 206:2191-204.
16. Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997; 15:2169-77.
17. Park JH, Okayama N, Gute D, Krsmanovic A, Battarbee H, Alexander JS. Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton. Am J Physiol 1999; 277:C1066-74.
18. Huang H, Rose JL, Hoyt DG. p38 Mitogen-activated protein kinase mediates synergistic induction of inducible nitric-oxide synthase by lipopolysaccharide and interferon-gamma through signal transducer and activator of transcription 1 Ser727 phosphorylation in murine aortic endothelial cells. Mol Pharmacol 2004; 66:302-11.
19. Borbiev T, Birukova A, Liu F et al. p38 MAP kinase-dependent regulation of endothelial cell permeability. Am J Physiol Lung Cell Mol Physiol 2004; 287:L911-8.
20. Roussel L, Houle F, Chan C et al. IL-17 promotes p38 MAPK-dependent endothelial activation enhancing neutrophil recruitment to sites of inflammation. J Immunol 2010; 184:4531-7.
21. Mudgett JS, Ding J, Guh-Siesel L et al. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97:10454-9.
22. Yang J, Boerm M, McCarty M et al. Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 2000; 24:309-13.
23. Gorska MM, Liang Q, Stafford SJ et al. MK2 controls the level of negative feedback in the NF-kappaB pathway and is essential for vascular permeability and airway inflammation. J Exp Med 2007; 204:1637-52.
24. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008; 67:909-16.
25. Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem 2002; 277:42596-602.
26. Ben-Levy R, Leighton IA, Doza YN et al. Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J 1995; 14:5920-30.
27. Kotlyarov A, Neininger A, Schubert C et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1:94-7.
28. Hoffmann A, Levchenko A, Scott ML, Baltimore D. The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 2002; 298:1241-5.
29. Tian B, Nowak DE, Brasier AR. A TNF-induced gene expression program under oscillatory NF-kappaB control. BMC Genomics 2005; 6:137-54.
30. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003; 22:1313-24.
31. McCoy CE, Campbell DG, Deak M, Bloomberg GB, Arthur JS. MSK1 activity is controlled by multiple phosphorylation sites. Biochem J 2005; 387:507-17.
32. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J 1998; 17:4426-41.
33. Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998; 8:1049-57.
34. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, Bavendiek U. Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 2007; 101:1104-12.
35. Sugawara T, Moriguchi T, Nishida E, Takahama Y. Differential roles of ERK and p38 MAP kinase pathways in positive and negative selection of T lymphocytes. Immunity 1998; 9:565-74.
36. Werlen G, Hausmann B, Palmer E. A motif in the alphabeta T-cell receptor controls positive selection by modulating ERK activity. Nature 2000; 406:422-6.
37. Fischer AM, Katayama CD, Pagès G, Pouysségur J, Hedrick SM. The role of erk1 and erk2 in multiple stages of T cell development. Immunity 2005; 23:431-43.
38. Sharp LL, Schwarz DA, Bott CM, Marshall CJ, Hedrick SM. The influence of the MAPK pathway on T cell lineage commitment. Immunity 1997; 7:609-18.
39. Pagès G, Guérin S, Grall D et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286:1374-7.
40. Nekrasova T, Shive C, Gao Y et al. ERK1-deficient mice show normal T cell effector function and are highly susceptible to experimental autoimmune encephalomyelitis. J Immunol 2005; 175:2374-80.
41. Agrawal A, Dillon S, Denning TL, Pulendran B. ERK1-/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J Immunol 2006; 176:5788-96.
42. Nakayama T, Yamashita M. The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin Immunol 2010; 22:303-9.
43. Yamashita M, Kimura M, Kubo M et al. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci USA 1999; 96:1024-9.
44. Duan W, Chan JH, Wong CH, Leung BP, Wong WS. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol 2004; 172:7053-9.
45. Dong C, Yang DD, Wysk M, Whitmarsh AJ, Davis RJ, Flavell RA. Defective T cell differentiation in the absence of Jnk1. Science 1998; 282:2092-5.
46. Yang DD, Conze D, Whitmarsh AJ et al. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 9:575-85.
47. Dong C, Yang DD, Tournier C et al. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000; 405:91-4.
48. Sohn SJ, Sarvis BK, Cado D, Winoto A. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 2002; 277:43344-51.
49. Ananieva O, Macdonald A, Wang X et al. ERK5 regulation in naïve T-cell activation and survival. Eur J Immunol 2008; 38:2534-47.
50. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest 2004; 113:619-27.
51. Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase(MEK-ERK) pathway. J Allergy Clin Immunol 2004; 114:1059-69.
52. Goleva E, Li LB, Leung DY. IFN-gamma reverses IL-2- and IL-4-mediated T-cell steroid resistance. Am J Respir Cell Mol Biol 2009; 40:223-30.
53. Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol 1998; 275 (Part 1):C623-33.
54. Adachi T, Choudhury BK, Stafford S, Sur S, Alam R. The differential role of extracellular signal-regulated kinases and p38 mitogen-activated protein kinase in eosinophil functions. J Immunol 2000; 165:2198-204.
55. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R. The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med 1995; 181:1827-34.
56. Kampen GT, Stafford S, Adachi T et al. Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. Blood 2000; 95:1911-7.
57. Goplen N, Gorska MM, Stafford SJ et al. A phosphosite screen identifies autocrine TGF-beta-driven activation of protein kinase R as a survival-limiting factor for eosinophils. J Immunol 2008; 180:4256-64.
58. Pazdrak K, Olszewska-Pazdrak B, Stafford S, Garofalo RP, Alam R. Lyn, Jak2, and Raf-1 kinases are critical for the antiapoptotic effect of interleukin 5, whereas only Raf-1 kinase is essential for eosinophil activation and degranulation. J Exp Med 1998; 188:421-9.
59. Bates ME, Green VL, Bertics PJ. ERK1 and ERK2 activation by chemotactic factors in human eosinophils is interleukin 5-dependent and contributes to leukotriene C(4) biosynthesis. J Biol Chem 2000; 275:10968-75.
60. Bates ME, Sedgwick JB, Zhu Y et al. Human airway eosinophils respond to chemoattractants with greater eosinophil-derived neurotoxin release, adherence to fibronectin, and activation of the Ras-ERK pathway when compared with blood eosinophils. J Immunol 2010; 184:7125-33.
61. Tsai M, Chen RH, Tam SY, Blenis J, Galli SJ. Activation of MAP kinases, pp90rsk and pp70-S6 kinases in mouse mast cells by signaling through the c-kit receptor tyrosine kinase or Fc epsilon RI: rapamycin inhibits activation of pp70-S6 kinase and proliferation in mouse mast cells. Eur J Immunol 1993; 23:3286-91.
62. Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. J Immunol 1995; 154:5391-402.
63. McDaniel AS, Allen JD, Park SJ et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood 2008; 112:4646-54.
64. Möller C, Alfredsson J, Engström M et al. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEK-regulated phosphorylation of the proapoptotic protein Bim. Blood 2005; 106:1330-6.
65. Garrington TP, Ishizuka T, Papst PJ et al. MEKK2 gene disruption causes loss of cytokine production in response to IgE and c-Kit ligand stimulation of ES cell-derived mast cells. EMBO J 2000; 19:5387-95.
66. Kimata M, Inagaki N, Kato T, Miura T, Serizawa I, Nagai H. Roles of mitogen-activated protein kinase pathways for mediator release from human cultured mast cells. Biochem Pharmacol 2000; 60:589-94.
67. Frossi B, Rivera J, Hirsch E, Pucillo C. Selective activation of Fyn/PI3K and p38 MAPK regulates IL-4 production in BMMC under nontoxic stress condition. J Immunol 2007; 178:2549-55.
68. Gomez G, Gonzalez-Espinosa C, Odom S et al. Impaired FcepsilonRI-dependent gene expression and defective eicosanoid and cytokine production as a consequence of Fyn deficiency in mast cells. J Immunol 2005; 175:7602-10.
69. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 2001; 166:3837-45.
70. Puig-Kröger A, Relloso M, Fernández-Capetillo O et al. Extracellular signal-regulated protein kinase signaling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 2001; 98:2175-82.
71. Luft T, Maraskovsky E, Schnurr M et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 2004; 104:1066-74.
72. Goplen N, Karim MZ, Liang Q et al. Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and establishes chronic features of asthma. J Allergy Clin Immunol 2009; 123:925-32.
73. Xia CQ, Peng R, Beato F, Clare-Salzler MJ. Dexamethasone induces IL-10-producing monocyte-derived dendritic cells with durable immaturity. Scand J Immunol 2005; 62:45-54.
74. Qian C, Jiang X, An H et al. TLR agonists promote ERK-mediated preferential IL-10 production of regulatory dendritic cells (diffDCs), leading to NK-cell activation. Blood 2006; 108:2307-15.
75. Dillon S, Agrawal A, Van Dyke T et al. A Toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signal-regulated kinase mitogen-activated protein kinase and c-Fos in dendritic cells. J Immunol 2004; 172:4733-43.
76. Dillon S, Agrawal S, Banerjee K et al. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest 2006; 116:916-28.
77. Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999; 162:4246-52.
78. Baldassare JJ, Bi Y, Bellone CJ. The role of p38 mitogen-activated protein kinase in IL-1 beta transcription. J Immunol 1999; 162:5367-73.
79. Ajizian SJ, English BK, Meals EA. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis 1999; 179:939-44.
80. Chen C, Chen YH, Lin WW. Involvement of p38 mitogen-activated protein kinase in lipopolysaccharide-induced iNOS and COX-2 expression in J774 macrophages. Immunology 1999; 97:124-9.
81. Yeo SJ, Gravis D, Yoon JG, Yi AK. Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38. J Biol Chem 2003; 278:22563-73.
82. Kim C, Sano Y, Todorova K et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 2008; 9:1019-27.
83. Lucas M, Zhang X, Prasanna V, Mosser DM. ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 2005; 175:469-77.
84. Chang CI, Zoghi B, Liao JC, Kuo L. The involvement of tyrosine kinases, cyclic AMP/protein kinase A, and p38 mitogen-activated protein kinase in IL-13-mediated arginase I induction in macrophages: its implications in IL-13-inhibited nitric oxide production. J Immunol 2000; 165:2134-41.
85. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 1989; 170:499-509.
86. Tang C, Inman MD, van Rooijen N et al. Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-gamma-dependent mechanism. J Immunol 2001; 166:1471-81.
87. Page TH, Brown A, Timms EM, Foxwell BM, Ray KP. p38 inhibitors suppress cytokine production in RA synovial membranes: does variable inhibition of IL-6 production limit effectiveness in vivo? Arthritis Rheum 2010; 62:3221-31.
88. Espelin CW, Goldsipe A, Sorger PK, Lauffenburger DA, de Graaf D, Hendriks BS. Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line. Mol Biosyst 2010; 6:1956-72.
89. Hammaker D, Firestein GS. "Go upstream, young man": lessons learned from the p38 saga. Ann Rheum Dis 2010; 69 (Suppl. 1):i77-82.
90. Yasuda T, Sanjo H, Pagès G et al. Erk kinases link pre-B cell receptor signaling to transcriptional events required for early B cell expansion. Immunity 2008; 28:499-508.
91. Kurosaki T, Shinohara H, Baba Y. B cell signaling and fate decision. Annu Rev Immunol 2010; 28:21-55.
92. Hashimoto A, Okada H, Jiang A et al. Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med 1998; 188:1287-95.
93. Richards JD, Davé SH, Chou CH, Mamchak AA, DeFranco AL. Inhibition of the MEK/ERK signaling pathway blocks a subset of B cell responses to antigen. J Immunol 2001; 166:3855-64.
94. Sanjo H, Hikida M, Aiba Y et al. Extracellular signal-regulated protein kinase 2 is required for efficient generation of B cells bearing antigen-specific immunoglobulin G. Mol Cell Biol 2007; 27:1236-46.
95. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat Immunol 2003; 4:594-600.
96. Gallagher E, Enzler T, Matsuzawa A et al. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 2007; 8:57-63.
97. Yamada T, Zhu D, Zhang K, Saxon A. Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc gamma-Fc epsilon chimeric protein. J Biol Chem 2003; 278:32818-24.
98. Zhang K, Zhang L, Zhu D, Bae D, Nel A, Saxon A. CD40-mediated p38 mitogen-activated protein kinase activation is required for immunoglobulin class switch recombination to IgE. J Allergy Clin Immunol 2002; 110:421-8.
99. Altan-Bonnet G, Germain RN. Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol 2005; 3:e356.
100. Legewie S, Schoeberl B, Blüthgen N, Herzel H. Competing docking interactions can bring about bistability in the MAPK cascade. Biophys J 2007; 93:2279-88.
101. Markevich NI, Hoek JB, Kholodenko BN. Signaling switches and bistability arising from multisite phosphorylation in protein kinase cascades. J Cell Biol 2004; 164:353-9.
102. Sethna J. What is hysteresis? Available at (accessed 1 June 2010).
103. Yildirim N, Santillan M, Horike D, Mackey MC. Dynamics and bistability in a reduced model of the lac operon. Chaos 2004; 14:279-92.
104. Lisman JE. A mechanism for memory storage insensitive to molecular turnover: a bistable autophosphorylating kinase. Proc Natl Acad Sci USA 1985; 82:3055-7.
105. Ferrell JE, Xiong W. Bistability in cell signaling: how to make continuous processes discontinuous, and reversible processes irreversible. Chaos 2001; 11:227-36.
106. Xiong W, Ferrell JE Jr. A positive-feedback-based bistable 'memory module' that governs a cell fate decision. Nature 2003; 426:460-5.
107. Bhalla US, Ram PT, Iyengar R. MAP kinase phosphatase as a locus of flexibility in a mitogen-activated protein kinase signaling network. Science 2002; 297:1018-23.
108. Lin J, Harding A, Giurisato E, Shaw AS. KSR1 modulates the sensitivity of mitogen-activated protein kinase pathway activation in T cells without altering fundamental system outputs. Mol Cell Biol 2009; 29:2082-91.
109. Bagowski CP, Ferrell JE Jr. Bistability in the JNK cascade. Curr Biol 2001; 11:1176-82.
110. Das J, Ho M, Zikherman J et al. Digital signaling and hysteresis characterize ras activation in lymphoid cells. Cell 2009; 136:337-51.
111. Inder K, Harding A, Plowman SJ, Philips MR, Parton RG, Hancock JF. Activation of the MAPK module from different spatial locations generates distinct system outputs. Mol Biol Cell 2008; 19:4776-84.
112. Kelleher RJ III, Govindarajan A, Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 2004; 44:59-73.
113. Giovannini MG. The role of the extracellular signal-regulated kinase pathway in memory encoding. Rev Neurosci 2006; 17:619-34.
114. Kelleher RJ III, Govindarajan A, Jung HY, Kang H, Tonegawa S. Translational control by MAPK signaling in long-term synaptic plasticity and memory. Cell 2004; 116:467-79.
115. Davis S, Vanhoutte P, Pages C, Caboche J, Laroche S. The MAPK/ERK cascade targets both Elk-1 and cAMP response element-binding protein to control long-term potentiation-dependent gene expression in the dentate gyrus in vivo. J Neurosci 2000; 20:4563-72.
116. Satoh Y, Endo S, Ikeda T et al. Extracellular signal-regulated kinase 2 (ERK2) knockdown mice show deficits in long-term memory; ERK2 has a specific function in learning and memory. J Neurosci 2007; 27:10765-76.
117. Miyashita Y. Cognitive memory: cellular and network machineries and their top-down control. Science 2004; 306:435-40.
118. Ofen-Noy N, Dudai Y, Karni A. Skill learning in mirror reading: how repetition determines acquisition. Brain Res Cogn Brain Res 2003; 17:507-21.
119. Gern JE. Viral and bacterial infections in the development and progression of asthma. J Allergy Clin Immunol 2000; 105:S497-502.
120. Martinez FD. Viruses and atopic sensitization in the first years of life. Am J Respir Crit Care Med 2000; 162:S95-9.
121. Liu W, Tundwal K, Liang Q et al. Establishment of extracellular signal-regulated kinase 1/2 bistability and sustained activation through Sprouty 2 and its relevance for epithelial function. Mol Cell Biol 2010; 30:1783-99.
122. Yang C, Zhou W, Jeon MS et al. Negative regulation of the E3 ubiquitin ligase itch via Fyn-mediated tyrosine phosphorylation. Mol Cell 2006; 21:135-41.
123. Gao M, Labuda T, Xia Y et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 2004; 306:271-5.
124. Egan JE, Hall AB, Yatsula BA, Bar-Sagi D. The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proc Natl Acad Sci USA 2002; 99:6041-6.
125. Wong ES, Fong CW, Lim J et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO J 2002; 21:4796-808.
126. Rubin C, Litvak V, Medvedovsky H, Zwang Y, Lev S., Yarden Y. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol 2003; 13:297-307.
127. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447:972-8.
128. Bashor CJ, Helman NC, Yan S, Lim WA Using engineered scaffold interactions to reshape MAP kinase pathway signaling dynamics. Science 2008; 319:1539-43.
129. Bhattacharyya RP, Reményi A, Good MC, Bashor CJ, Falick AM, Lim WA. The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. Science 2006; 311:822-6.
130. Giorgetti L, Siggers T, Tiana G et al. Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. Mol Cell 2010; 37:418-28.